Physician profile
Charles E Moore
NPI 1629038609
$2,965.82
in general payments reported to CMS, 2019-2025
25 companies · $279 in 2025
The $279 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $756 · 2020: $385 · 2021: $536 · 2022: $504 · 2023: $109 · 2024: $397 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $785.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $785.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,196.59 | 2019-2024 | Airsupra, Farxiga |
| Lilly USA, LLC | $305.81 | 2019-2025 | Mounjaro |
| Abbvie INC. | $258.76 | 2021-2024 | |
| Glaxosmithkline, LLC. | $204.36 | 2019-2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $202.91 | 2019-2024 | Evenity, Prolia, Repatha |
| Dexcom, INC. | $124.93 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Janssen Pharmaceuticals, INC | $114.70 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $113.67 | 2025 | Zoryve |
| Novo Nordisk INC | $98.15 | 2022-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $34.15 | 2021-2024 | |
| Bausch Health US, LLC | $32.03 | 2020-2021 | |
| Janssen Biotech, INC. | $31.18 | 2024 | Tremfya |
| Biohaven Pharmaceutical Holding Company Ltd. | $29.61 | 2022 | |
| Amag Pharmaceuticals, INC. | $29.18 | 2019-2020 | |
| Exeltis, USA INC. | $27.33 | 2022-2023 | Slynd |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $24.18 | 2019 | |
| Antares Pharma, INC. | $20.45 | 2019 | |
| Roche Diagnostics Corporation | $19.99 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.31 | 2020 | |
| Genentech USA, INC. | $15.47 | 2019 | |
| Currax Pharmaceuticals LLC | $15.43 | 2020 | |
| Vifor Pharma, INC. | $14.63 | 2021 | |
| Abbott Laboratories | $12.29 | 2021 | |
| Merck Sharp & Dohme LLC | $11.59 | 2019 | |
| Daiichi Sankyo INC. | $11.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.